| $350M | ||
| $241M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $47,270,139 | 40 | 100 |
| Krishnan Mahesh | director | 0 | $0 | 1 | $547,800 | $-547,800 |
| Connaughton Bernadette | director | 0 | $0 | 6 | $702,406 | $-702,406 |
| Caudill Cortney | SVP, CHIEF OPERATING OFFICER | 0 | $0 | 2 | $1.96M | $-1.96M |
| Posard Matthew L. | director | 0 | $0 | 2 | $2.61M | $-2.61M |
| Torley Helen | PRESIDENT AND CEO | 0 | $0 | 30 | $42.83M | $-42.83M |
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
Over the last 12 months, insiders at Halozyme Therapeutics, Inc. have bought $0 and sold $47.27M worth of Halozyme Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Halozyme Therapeutics, Inc. have bought $0 and sold $28.6M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 52,629 shares for transaction amount of $748,697 was made by Kelley Kenneth J (director) on 2020‑03‑19.
| 2026-10-08 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.0168% | $109.40 | $2.19M | +12.59% | |
| 2026-10-07 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.017% | $111.55 | $2.23M | +10.98% | |
| 2026-10-06 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.0168% | $109.58 | $2.19M | +11.86% | |
| 2026-10-01 | Sale | Posard Matthew L. | director | 5,230 0.0045% | $108.54 | $567,661 | +13.93% | |
| 2026-09-16 | Sale | Posard Matthew L. | director | 18,996 0.0159% | $107.74 | $2.05M | +4.57% | |
| 2026-09-11 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.0169% | $107.24 | $2.14M | +4.90% | |
| 2026-09-10 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.0169% | $107.17 | $2.14M | +5.09% | |
| 2026-09-09 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.0169% | $107.43 | $2.15M | +4.70% | |
| 2026-08-19 | Sale | Torley Helen | PRESIDENT AND CEO | 16,800 0.0141% | $106.85 | $1.8M | +2.58% | |
| 2026-08-19 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.0168% | $107.00 | $2.14M | +2.58% | |
| 2026-08-18 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.0167% | $104.18 | $2.08M | +5.15% | |
| 2026-08-17 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.017% | $102.60 | $2.05M | +6.98% | |
| 2026-08-10 | Sale | Connaughton Bernadette | director | 1,626 0.0014% | $102.80 | $167,153 | +6.98% | |
| 2026-07-08 | Sale | Torley Helen | PRESIDENT AND CEO | 1,923 0.0016% | $79.77 | $153,391 | +34.03% | |
| 2026-07-01 | Sale | Connaughton Bernadette | director | 1,625 0.0014% | $76.71 | $124,651 | +39.45% | |
| 2026-06-29 | Sale | Krishnan Mahesh | director | 7,304 0.006% | $75.00 | $547,800 | +38.90% | |
| 2026-06-03 | Sale | Torley Helen | PRESIDENT AND CEO | 3,900 0.0032% | $68.09 | $265,532 | +50.56% | |
| 2026-06-03 | Sale | Torley Helen | PRESIDENT AND CEO | 10,000 0.0088% | $69.07 | $690,653 | +50.56% | |
| 2026-06-02 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.0169% | $66.39 | $1.33M | +58.25% | |
| 2026-06-01 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.0167% | $67.58 | $1.35M | +53.01% |
| Torley Helen | PRESIDENT AND CEO | 767780 0.6734% | $78.07M | 1 | 91 | +68.25% |
| Posard Matthew L. | director | 53609 0.047% | $5.45M | 0 | 10 | |
| Connaughton Bernadette | director | 40418 0.0355% | $4.11M | 0 | 9 | |
| Krishnan Mahesh | director | 14462 0.0127% | $1.47M | 0 | 1 | |
| Caudill Cortney | SVP, CHIEF OPERATING OFFICER | 7055 0.0062% | $717,352.40 | 0 | 3 | |
| Frost Gregory Ian | CEO, President | 3555331 3.1184% | $361.51M | 4 | 16 | +20.07% |
| KIRK RANDAL J | 10 percent owner | 1897610 1.6644% | $192.95M | 56 | 18 | +103.3% |
| Lim Jonathan E | President, CEO | 680000 0.5964% | $69.14M | 1 | 8 | +18.01% |
| RAMSAY DAVID A | VP and Chief Financial Officer | 323492 0.2837% | $32.89M | 7 | 3 | +24.44% |
| FALBERG KATHRYN E | director | 280000 0.2456% | $28.47M | 3 | 0 | +46.53% |
| Engler Robert | director | 273176 0.2396% | $27.78M | 5 | 3 | +18.07% |
| MATSUI CONNIE | director | 181983 0.1596% | $18.5M | 0 | 2 | |
| PATTON JOHN STUART | director | 179876 0.1578% | $18.29M | 0 | 22 | |
| Kelley Kenneth J | director | 179833 0.1577% | $18.29M | 3 | 22 | +50.56% |
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | 173756 0.1524% | $17.67M | 0 | 48 | |
| Yocum Richard C | VP Clinical Development | 65975 0.0579% | $6.71M | 0 | 1 | |
| BIZZARI JEAN-PIERRE | director | 52544 0.0461% | $5.34M | 0 | 1 | |
| Chondros Dimitrios | SVP, Chief Medical Officer | 38584 0.0338% | $3.92M | 0 | 2 | |
| Henderson Jeffrey William | director | 28611 0.0251% | $2.91M | 0 | 8 | |
| Shaffer James P | VP & Chief Commercial Officer | 26300 0.0231% | $2.67M | 1 | 0 | +34.45% |
| LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | 22079 0.0194% | $2.24M | 0 | 8 | |
| Daly James M | director | 20503 0.018% | $2.08M | 0 | 4 | |
| Thornton Steven T | director | 15000 0.0132% | $1.53M | 0 | 3 | |
| Shepard H. Michael | VP, Chief Scientific Officer | 13198 0.0116% | $1.34M | 0 | 1 | |
| LITTLE ROBERT J | VP, Chief Commercial Officer | 13000 0.0114% | $1.32M | 2 | 0 | <0.0001% |
| Stelzer Laurie | Chief Financial Officer | 10000 0.0088% | $1.02M | 1 | 0 | <0.0001% |
| GUSTAFSON KURT A | Vice President and CFO | 8000 0.007% | $813,440.00 | 1 | 0 | |
| Kennard Don A | Vice President, Regulatory Aff | 3000 0.0026% | $305,040.00 | 1 | 0 | +31.79% |
$961,890,236 | 276 | 22.46% | $24.92B | |
$273,531,368 | 93 | 38.24% | $10.06B | |
$2,765,836 | 72 | 20.00% | $11.3B | |
Halozyme Therapeutics, Inc. (HALO) | $108,876,545 | 67 | 72.81% | $11.59B |
$11,991,408 | 51 | 18.36% | $26.49B | |
$323,530,732 | 48 | 29.90% | $21.41B | |
$98,300,471 | 40 | 0.27% | $15.93B | |
$19,233,721 | 36 | 70.14% | $17.77B | |
$13,655,378 | 35 | 17.13% | $25.37B | |
$650,670,576 | 22 | 96.65% | $13.27B | |
$415,090,639 | 19 | -14.04% | $15.49B | |
$118,094,211 | 15 | 38.32% | $11.51B | |
$9,976,473 | 12 | 29.52% | $9.68B | |
$35,908,794 | 10 | 126.31% | $8.8B | |
$11,898,979 | 10 | 54.58% | $9.15B | |
$948,235 | 8 | 15.54% | $11.44B | |
$2,246,813 | 6 | 70.15% | $9.94B | |
$40,326,230 | 5 | 44.68% | $30.32B | |
$41,376,000 | 4 | -12.07% | $10.8B |
| Increased Positions | 332 | +48.12% | 18M | +14.8% |
| Decreased Positions | 309 | -44.78% | 15M | -12.14% |
| New Positions | 106 | New | 5M | New |
| Sold Out Positions | 79 | Sold Out | 4M | Sold Out |
| Total Postitions | 713 | +3.33% | 124M | +2.66% |
| Blackrock, Inc. | $904,201.00 | 10.9% | 12.86M | -339,833 | -2.57% | 2025-09-30 |
| Vanguard Group Inc | $817,690.00 | 9.86% | 11.63M | -615,816 | -5.03% | 2025-09-30 |
| State Street Corp | $352,900.00 | 4.25% | 5.02M | -915,838 | -15.43% | 2025-09-30 |
| Arrowstreet Capital, Limited Partnership | $231,367.00 | 2.79% | 3.29M | +749,484 | +29.49% | 2025-09-30 |
| Invesco Ltd. | $228,210.00 | 2.75% | 3.25M | -220,119 | -6.35% | 2025-09-30 |
| Ubs Group Ag | $207,116.00 | 2.5% | 2.95M | +1M | +93.24% | 2025-09-30 |
| Snyder Capital Management L P | $192,217.00 | 2.32% | 2.73M | -663,853 | -19.54% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $186,348.00 | 2.25% | 2.65M | +2M | +160.15% | 2025-09-30 |
| Geode Capital Management, Llc | $170,943.00 | 2.06% | 2.43M | -1,230 | -0.05% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $146,134.00 | 1.76% | 2.08M | +63,699 | +3.16% | 2025-09-30 |